The fate of bacillus Calmette-Guerin after intravesical instillation
- PMID: 11342972
The fate of bacillus Calmette-Guerin after intravesical instillation
Abstract
Purpose: Long-term activation of immunocompetent cells of the bladder wall as well as case reports of systemic infections some months or years after intravesical bacillus Calmette-Guerin (BCG) therapy imply that mycobacteria may persist in the body. Therefore. we investigated the fate of BCG in patients after uncomplicated intravesical instillation therapy.
Material and methods: A total of 49 patients were included in the study, from whom various numbers of specimens were used for mycobacterial culture and molecular biological detection techniques. In 23 patients who received a total of 128 instillations urine, sputum, venous blood and bladder biopsies were screened for BCG by acid-fast staining and culture at different times before and after instillation. From 16 of the 23 patients and from an additional 26 a total of 180 bladder biopsies obtained at intervals 3 to 30 months after instillation were screened for mycobacterial 16S ribosomal DNA by a nested polymerase chain reaction protocol.
Results: No viable BCG was found in venous blood or in 127 of 128 sputum specimens before and 2 hours after instillation. Two of 56 bladder biopsies were culture positive. In urine BCG was detected in 96.4% of the specimens after 2 hours and in 67.9% after 24 hours after instillation. The number of positive specimens decreased and it was 27.1% on day 7 immediately before the next instillation. In 14 of 44 bladder biopsies (31.8%) mycobacterial ribosomal DNA was found within 1 week after the sixth instillation. A positive polymerase chain reaction was evident up to 24 months in between 4.2% and 37.5% of the investigated biopsies. After 30 months no ribosomal DNA was evident in the 6 samples available for testing.
Conclusions: Nontraumatic intravesical instillation of BCG is not accompanied by systemic mycobacterial spread. Local persistence during the instillation course is evident since viable BCG is commonly found in the urine. Long lasting and persistent BCG DNA in the bladder wall may account for long-term immuno-activation. However, the remaining BCG may be a possible source of late systemic infections.
Similar articles
-
Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.Int J Urol. 2007 Feb;14(2):140-6. doi: 10.1111/j.1442-2042.2007.01696.x. Int J Urol. 2007. PMID: 17302571
-
[Two cases of successful treatments with steroid for local and systemic hypersensitivity reaction following intravesical instillation of Bacillus Calmette-Guerin].Hinyokika Kiyo. 2001 Apr;47(4):281-4. Hinyokika Kiyo. 2001. PMID: 11411106 Japanese.
-
Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette-Guerin instillation for bladder carcinoma.Am J Gastroenterol. 1993 Jul;88(7):1112-5. Am J Gastroenterol. 1993. PMID: 8317415
-
[A case of renal tuberculosis following bacillus Calmette-Guerin instillation therapy for bladder cancer].Hinyokika Kiyo. 2000 Feb;46(2):109-11. Hinyokika Kiyo. 2000. PMID: 10769800 Review. Japanese.
-
[Calmette-Guerin bacillus disseminated infection after intravesical instillation].Recenti Prog Med. 2002 Apr;93(4):247-8. Recenti Prog Med. 2002. PMID: 11989131 Review. Italian.
Cited by
-
Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches.Pharmaceutics. 2024 Aug 15;16(8):1067. doi: 10.3390/pharmaceutics16081067. Pharmaceutics. 2024. PMID: 39204412 Free PMC article. Review.
-
Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer.Cancer Immunol Immunother. 2023 Jan;72(1):125-136. doi: 10.1007/s00262-022-03236-y. Epub 2022 Jun 24. Cancer Immunol Immunother. 2023. PMID: 35748904 Free PMC article.
-
Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy.Oncoimmunology. 2020 Apr 21;9(1):1748981. doi: 10.1080/2162402X.2020.1748981. eCollection 2020. Oncoimmunology. 2020. PMID: 32363120 Free PMC article. Clinical Trial.
-
Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer.Can Urol Assoc J. 2007 Sep;1(3):269-72. doi: 10.5489/cuaj.83. Can Urol Assoc J. 2007. PMID: 18542802 Free PMC article.
-
Non-muscle invasive bladder cancer in a pregnant patient.Urol Case Rep. 2025 Jul 4;62:103119. doi: 10.1016/j.eucr.2025.103119. eCollection 2025 Sep. Urol Case Rep. 2025. PMID: 40686516 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical